03:45 AM EDT, 05/20/2026 (MT Newswires) -- Prostatype Genomics (PROGEN.ST) said Wednesday it intends to raise up to 47.4 million kronor through a rights issue of units, including shares and two series of warrants, with preferential rights.

The subscription period will run from July 9 to July 23, with the prognostic gene test provider expected to raise an additional 60 million kronor through the attached series TO6 and TO7 warrants, which entitle holders to subscribe for one new share each.

The proceeds will be used to support the ongoing Medicare approval process and commercialization activities for the company's Prostatype genetic test in the US and Europe, as well as ongoing operating expenses.

Assuming full subscription of the rights Issue and full exercise of the warrants at the maximum exercise price, the proceeds are expected to fund operations through the fourth quarter of 2027.